MEDNAX Inc (MD) Given Average Recommendation of “Hold” by Analysts

Shares of MEDNAX Inc (NYSE:MD) have been assigned a consensus recommendation of “Hold” from the sixteen research firms that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $53.82.

A number of equities analysts recently issued reports on MD shares. KeyCorp upgraded shares of MEDNAX from a “sector weight” rating to an “overweight” rating and set a $51.00 price objective for the company in a research report on Sunday, September 17th. Jefferies Group reissued a “hold” rating and set a $46.00 target price on shares of MEDNAX in a report on Tuesday, October 3rd. Zacks Investment Research raised shares of MEDNAX from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. BMO Capital Markets began coverage on shares of MEDNAX in a report on Monday, October 16th. They set a “market perform” rating and a $46.00 target price on the stock. Finally, Robert W. Baird boosted their target price on shares of MEDNAX from $47.00 to $48.00 and gave the stock a “neutral” rating in a report on Friday, November 3rd.

In other news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total value of $154,740.00. Following the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at approximately $1,834,649.02. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Cesar L. Alvarez sold 10,668 shares of the company’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $42.59, for a total transaction of $454,350.12. Following the completion of the sale, the director now directly owns 44,215 shares in the company, valued at $1,883,116.85. The disclosure for this sale can be found here. Insiders own 2.40% of the company’s stock.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of MEDNAX by 0.3% in the 2nd quarter. BlackRock Inc. now owns 8,257,495 shares of the company’s stock valued at $498,505,000 after purchasing an additional 28,155 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of MEDNAX by 0.5% during the 2nd quarter. Vanguard Group Inc. now owns 7,551,130 shares of the company’s stock valued at $455,862,000 after acquiring an additional 38,645 shares during the period. Thompson Siegel & Walmsley LLC lifted its position in shares of MEDNAX by 19.7% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 2,598,925 shares of the company’s stock valued at $112,065,000 after acquiring an additional 428,184 shares during the period. Nordea Investment Management AB lifted its position in shares of MEDNAX by 4.8% during the 3rd quarter. Nordea Investment Management AB now owns 2,323,695 shares of the company’s stock valued at $100,198,000 after acquiring an additional 106,883 shares during the period. Finally, Earnest Partners LLC lifted its position in shares of MEDNAX by 0.7% during the 3rd quarter. Earnest Partners LLC now owns 1,494,374 shares of the company’s stock valued at $64,437,000 after acquiring an additional 11,037 shares during the period. 98.43% of the stock is currently owned by institutional investors.

MEDNAX (MD) traded down $0.11 during mid-day trading on Monday, reaching $54.50. 1,116,700 shares of the company were exchanged, compared to its average volume of 956,375. The firm has a market cap of $5,104.21, a PE ratio of 19.26, a price-to-earnings-growth ratio of 1.64 and a beta of 0.39. MEDNAX has a twelve month low of $40.56 and a twelve month high of $72.13. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.37 and a current ratio of 1.37.

MEDNAX (NYSE:MD) last released its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.87. The business had revenue of $868.95 million during the quarter, compared to analysts’ expectations of $864.78 million. MEDNAX had a net margin of 7.76% and a return on equity of 10.80%. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.09 EPS. analysts predict that MEDNAX will post 3.1 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “MEDNAX Inc (MD) Given Average Recommendation of “Hold” by Analysts” was first published by BBNS and is the sole property of of BBNS. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://baseballnewssource.com/markets/mednax-inc-md-given-average-recommendation-of-hold-by-analysts/1818282.html.

MEDNAX Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Analyst Recommendations for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.